Can a new injection help tackle obesity and diabetes? a safety trial begins

NCT ID NCT07736391

Ongoing Disease control Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This early-stage trial tests an experimental drug called SYH2069, given as an injection under the skin, in healthy volunteers. The goal is to see if it is safe and how the body processes it at different doses. The study includes people who are overweight or obese, as the drug is being developed for weight management and diabetes. Volunteers receive either the drug or a placebo, and researchers monitor for side effects and measure drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental injection called SYH2069
What this could lead to: If safe, this could lead to a new treatment option for weight management and diabetes.
What could go wrong: This is an early phase 1 trial in healthy people, so it is too soon to know if it works or what side effects may occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES OVERWEIGHT OR OBESITY

Contacts and locations

Locations

The Affiliated Hospital of Nanjing University Medical School

Nanjing, Jiangsu, 210008, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.